Question

Plasma protein bound drugs are:

• A. Pharmacodynamically active
• B. Pharmacokinetically inert
• C. Pharmacokinetically and Pharmacodynamically inert
• D. Pharmacodynamically inert

Hint:

Only the free drug fraction is pharmacodynamically active. Plasma protein binding extends drug half-life but delays immediate pharmacological effects.

Answer 1

The Correct Option is D

Step 1: Understanding plasma protein binding. Many drugs bind to plasma proteins, primarily albumin. Only the free (unbound) drug is available for pharmacological action. The protein-bound fraction serves as a reservoir, gradually releasing the drug as the free form is metabolized or excreted. 

Step 2: Pharmacodynamic and pharmacokinetic implications. 
- Pharmacodynamically inert: Since bound drugs cannot interact with receptors or target tissues, they are pharmacodynamically inactive.
 - Pharmacokinetically active: Plasma-bound drugs can influence drug distribution and half-life but are not inert in pharmacokinetic terms. 

Step 3: Why other options are incorrect. - (A) Pharmacodynamically active: Incorrect, as only free drugs interact with receptors. 
- (B) Pharmacokinetically inert: Incorrect, as binding affects drug distribution and elimination. 
- (C) Pharmacokinetically and pharmacodynamically inert: Incorrect, because plasma-bound drugs influence pharmacokinetics but not pharmacodynamics.

Answer 2

The question asks how a drug behaves once it is bound to plasma proteins such as albumin. Since only free, unbound drug can act on a receptor or move across membranes, checking what "bound" does to both pharmacodynamic activity and pharmacokinetic behavior settles the answer.

1. Pharmacodynamically active: A bound drug molecule is too large and too tightly held to reach and engage its receptor. Only the free fraction produces a pharmacological effect, so calling the bound form pharmacodynamically active is incorrect.
2. Pharmacokinetically inert: Protein binding directly affects distribution, since a heavily bound drug stays largely within the vascular compartment, and it affects elimination, since bound drug is protected from metabolism and glomerular filtration. That is active pharmacokinetic influence, not inertness, so this option is wrong.
3. Pharmacokinetically and Pharmacodynamically inert: This would require the bound drug to have no effect on distribution or elimination at all, which contradicts the well documented role of protein binding as a circulating reservoir that shapes half life and volume of distribution.
4. Pharmacodynamically inert: The bound drug cannot interact with its target receptor while attached to the protein, so it produces no pharmacological action in that state. At the same time it still meaningfully affects pharmacokinetics, since it is only released gradually as free drug is cleared. This matches the description of a drug that is inactive at the receptor but pharmacokinetically significant.

The bound fraction is silent at the receptor but still shapes how the drug moves through and leaves the body, which is exactly what pharmacodynamically inert but pharmacokinetically active means.

Therefore, the correct answer is Pharmacodynamically inert.